The FDA Fast Track designation and successful $20 million financing materially de-risk stenoparib's development path; monitor upcoming clinical trial enrollment and data readouts as key catalysts. The new license revenue stream validates the DRP platform's commercial potential.
Price Chart
Executive Summary
Allarity Therapeutics reported full-year 2025 financial results, showing improved net loss of $11.2 million (vs $25.1 million in 2024) due to cost discipline, while securing a $20 million debt financing and receiving FDA Fast Track designation for stenoparib in advanced ovarian cancer. The company also launched a VA-funded combination trial in small cell lung cancer.
Key Financial Metrics
Key Facts
- Net loss improved to $11.2 million in 2025 from $25.1 million in 2024, excluding a $9.7 million non-cash impairment in 2024
- Received FDA Fast Track designation for stenoparib in advanced ovarian cancer
- Closed $20 million non-convertible debt financing with Streeterville Capital in March 2026
- Launched Phase 2 combination trial of stenoparib with temozolomide in recurrent small cell lung cancer, fully funded by the U.S. Veterans Administration
- Generated $320,000 in license revenue in 2025, compared to no revenue in 2024
Financial Impact
Net loss improved by $13.9 million year-over-year (excluding 2024 impairment), with $320,000 in new license revenue and $20 million in new debt financing
Risk Factors
- High cash burn rate despite improvements; $14.7 million cash at year-end 2025 may not cover runway to mid-2028 as projected
- Clinical trial delays or negative data could jeopardize Fast Track status and commercial prospects
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-038061 |
| Document: ea0279571-8k_allarity.htm | 0001213900-26-038061 |
| Document: 0001213900-26-038061-index-headers.html | 0001213900-26-038061 |
| Document: 0001213900-26-038061-index.html | 0001213900-26-038061 |
| Document: 0001213900-26-038061.txt | 0001213900-26-038061 |
| 8-K Data (Synthetic) | 0001213900-26-038061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9200 (−11.54%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 $0.9200 | ▼ −4.67% | ▼ −5.39% | $0.9200 (−4.67%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9200 (−5.00%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9200 (−20.35%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9200 (−21.37%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9200 (−24.59%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9200 (−32.85%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9200 (−30.83%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9200 (−32.35%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9200 (−35.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers